NASDAQ:AZRXAzurRx BioPharma Stock Price, Forecast & News

AzurRx BioPharma's stock was trading at $0.6150 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AZRX stock has increased by 52.8% and is now trading at $0.94. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AzurRx BioPharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AzurRx BioPharma.

AzurRx BioPharma is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for AzurRx BioPharma.

AzurRx BioPharma Inc (NASDAQ:AZRX) released its earnings results on Friday, May, 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.09. View AzurRx BioPharma's earnings history.

4 brokers have issued 12 month target prices for AzurRx BioPharma's shares. Their forecasts range from $2.00 to $9.00. On average, they anticipate AzurRx BioPharma's share price to reach $4.67 in the next year. This suggests a possible upside of 396.5% from the stock's current price. View analysts' price targets for AzurRx BioPharma.

News articles about AZRX stock have trended somewhat negative this week, InfoTrie reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. AzurRx BioPharma earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutAzurRx BioPharma.

AzurRx BioPharma saw a decrease in short interest in May. As of May 15th, there was short interest totaling 85,200 shares, a decrease of 22.1% from the April 30th total of 109,400 shares. Based on an average daily volume of 264,500 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.4% of the company's stock are short sold. View AzurRx BioPharma's Current Options Chain.

Some companies that are related to AzurRx BioPharma include Galmed Pharmaceuticals (GLMD), Corvus Pharmaceuticals (CRVS), Leap Therapeutics (LPTX), Catalyst Biosciences (CBIO), Genprex (GNPX), Clearside Biomedical (CLSD), Aptorum Group (APM), CannTrust (CTST), Assertio Therapeutics (ASRT), Milestone Pharmaceuticals (MIST), Oncolytics Biotech (ONCY), Otonomy (OTIC), Onconova Therapeutics (ONTX), Monopar Therapeutics (MNPR) and Sesen Bio (SESN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AzurRx BioPharma investors own include Outlook Therapeutics (OTLK), Amplify Energy (AMPY), Amplify Energy (AMPY), Unum Therapeutics (UMRX), Chesapeake Energy (CHK), Trevena (TRVN), ADMA Biologics (ADMA), Miragen Therapeutics (MGEN), Matinas BioPharma (MTNB) and Titan Pharmaceuticals (TTNP).

(AZRX) raised $15 million in an initial public offering on Friday, September 9th 2016. The company issued 2,100,000 shares at a price of $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities served as the underwriters for the IPO.

AzurRx BioPharma trades on the NASDAQ under the ticker symbol "AZRX."

AzurRx BioPharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Parsons Capital Management Inc. RI (1.04%), Tiedemann Advisors LLC (0.23%) and Pensionmark Financial Group LLC (0.18%). Company insiders that own AzurRx BioPharma stock include Charles J Casamento, Edmund Burke Jr Ross, Johan M Spoor and Maged Shenouda. View institutional ownership trends for AzurRx BioPharma.

AZRX stock was sold by a variety of institutional investors in the last quarter, including Tiedemann Advisors LLC, and Parsons Capital Management Inc. RI. View insider buying and selling activity for AzurRx BioPharma.

AZRX stock was acquired by a variety of institutional investors in the last quarter, including Pensionmark Financial Group LLC. Company insiders that have bought AzurRx BioPharma stock in the last two years include Charles J Casamento, Edmund Burke Jr Ross, Johan M Spoor, and Maged Shenouda. View insider buying and selling activity for AzurRx BioPharma.

Shares of AZRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AZRX stock can currently be purchased for approximately $0.94.

AzurRx BioPharma has a market capitalization of $26.51 million. AzurRx BioPharma employs 12 workers across the globe.

The official website for AzurRx BioPharma is www.azurrx.com.

AzurRx BioPharma's mailing address is 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226. The company can be reached via phone at 646-699-7855 or via email at [email protected]